Cargando…
Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886147/ https://www.ncbi.nlm.nih.gov/pubmed/31719297 http://dx.doi.org/10.4103/ijmr.IJMR_1209_17 |
_version_ | 1783474826772480000 |
---|---|
author | de Oliveira, Fabricio Ferreira Berretta, Juliana Marília de Almeida Junior, Guido Veiga de Almeida, Sandro Soares Chen, Elizabeth Suchi Smith, Marilia Cardoso Ferreira Bertolucci, Paulo Henrique |
author_facet | de Oliveira, Fabricio Ferreira Berretta, Juliana Marília de Almeida Junior, Guido Veiga de Almeida, Sandro Soares Chen, Elizabeth Suchi Smith, Marilia Cardoso Ferreira Bertolucci, Paulo Henrique |
author_sort | de Oliveira, Fabricio Ferreira |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses of the effects of angiotensin-converting enzyme (ACE) inhibitors and statins. METHODS: Consecutive patients were prospectively followed to study variations of creatinine clearance and blood pressure for one year, estimated by correlating the effects of ACE inhibitors with the ACE Alu I/D polymorphism and genotypes or haplotypes of rs1800764 or rs4291, and the effects of statins with LDLR (low-density lipoprotein receptor) genotypes or haplotypes of rs11669576 (exon 8) or rs5930 (exon 10), or genotypes of rs2695121 (liver X receptor β gene). Variations of the coronary heart disease (CHD) risk according to these cardiovascular measures were also explored. RESULTS: All polymorphisms of the 193 patients were in Hardy-Weinberg equilibrium. Genetic determinants of cardiovascular effects affected the individual variability of the response to ACE inhibitors and statins. ACE inhibitors, but not statins, reduced blood pressure for all patients. ACE inhibitors protected carriers of alleles that supposedly decrease serum ACE levels (rs1800764-T, rs4291-A, Alu II) regarding creatinine clearance variations (P<0.005), but carriers of Alu DD (P<0.02), rs1800764-C (P<0.05), or rs4291-AT (P<0.04) showed better blood pressure lowering effects. The presence of rs2695121-T (P=0.007) or rs5930-A (P=0.039) was associated with systolic blood pressure lowering, whereas rs5930-AA was protective against decrease in creatinine clearance (P=0.019). Statins lowered creatinine clearance for carriers of rs2695121-CT (P=0.026). INTERPRETATION & CONCLUSIONS: Pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins may be genetically mediated. |
format | Online Article Text |
id | pubmed-6886147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-68861472019-12-09 Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia de Oliveira, Fabricio Ferreira Berretta, Juliana Marília de Almeida Junior, Guido Veiga de Almeida, Sandro Soares Chen, Elizabeth Suchi Smith, Marilia Cardoso Ferreira Bertolucci, Paulo Henrique Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses of the effects of angiotensin-converting enzyme (ACE) inhibitors and statins. METHODS: Consecutive patients were prospectively followed to study variations of creatinine clearance and blood pressure for one year, estimated by correlating the effects of ACE inhibitors with the ACE Alu I/D polymorphism and genotypes or haplotypes of rs1800764 or rs4291, and the effects of statins with LDLR (low-density lipoprotein receptor) genotypes or haplotypes of rs11669576 (exon 8) or rs5930 (exon 10), or genotypes of rs2695121 (liver X receptor β gene). Variations of the coronary heart disease (CHD) risk according to these cardiovascular measures were also explored. RESULTS: All polymorphisms of the 193 patients were in Hardy-Weinberg equilibrium. Genetic determinants of cardiovascular effects affected the individual variability of the response to ACE inhibitors and statins. ACE inhibitors, but not statins, reduced blood pressure for all patients. ACE inhibitors protected carriers of alleles that supposedly decrease serum ACE levels (rs1800764-T, rs4291-A, Alu II) regarding creatinine clearance variations (P<0.005), but carriers of Alu DD (P<0.02), rs1800764-C (P<0.05), or rs4291-AT (P<0.04) showed better blood pressure lowering effects. The presence of rs2695121-T (P=0.007) or rs5930-A (P=0.039) was associated with systolic blood pressure lowering, whereas rs5930-AA was protective against decrease in creatinine clearance (P=0.019). Statins lowered creatinine clearance for carriers of rs2695121-CT (P=0.026). INTERPRETATION & CONCLUSIONS: Pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins may be genetically mediated. Wolters Kluwer - Medknow 2019-09 /pmc/articles/PMC6886147/ /pubmed/31719297 http://dx.doi.org/10.4103/ijmr.IJMR_1209_17 Text en Copyright: © 2019 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article de Oliveira, Fabricio Ferreira Berretta, Juliana Marília de Almeida Junior, Guido Veiga de Almeida, Sandro Soares Chen, Elizabeth Suchi Smith, Marilia Cardoso Ferreira Bertolucci, Paulo Henrique Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title | Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title_full | Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title_fullStr | Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title_full_unstemmed | Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title_short | Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia |
title_sort | pharmacogenetic analyses of variations of measures of cardiovascular risk in alzheimer's dementia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886147/ https://www.ncbi.nlm.nih.gov/pubmed/31719297 http://dx.doi.org/10.4103/ijmr.IJMR_1209_17 |
work_keys_str_mv | AT deoliveirafabricioferreira pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT berrettajulianamarilia pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT dealmeidajuniorguidoveiga pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT dealmeidasandrosoares pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT chenelizabethsuchi pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT smithmariliacardoso pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia AT ferreirabertoluccipaulohenrique pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia |